|
[µ¥Àϸ®¸Þµð Á¤¼÷°æ ±âÀÚ] °¡Å縯´ëÇб³ ¼¿ï¼º¸ðº´¿ø ¼±µµÇü ¸é¿ªÁúȯÀ¶ÇÕ¿¬±¸»ç¾÷´ÜÀº °¡Å縯Á¶Ç÷¸ð¼¼Æ÷ÀºÇà ¹× Àå±âÀ̽Ŀ¬±¸¼Ò¿Í Áö³ 12ÀÏ ½¦¶óÅæÆÈ·¡½º °³² È£ÅÚ¿¡¼ Á¶Á÷ÀûÇÕ¼ºÇ׿ø(Human Leukocyte Antigen, HLA)°Ë»ç¿¡ ´ëÇÑ ÃֽŠÁö°ßÀ» °øÀ¯ÇÏ´Â 'HLA SYMPOSIUM'À» °³ÃÖÇß´Ù.
Á¶Á÷ÀûÇÕ°Ë»ç¹ýÀº ¼º°øÀûÀÎ Àå±âÀ̽İú Á¶Ç÷¸ð¼¼Æ÷À̽ÄÀ» À§ÇÑ ÇʼöÀû ¸é¿ª°Ë»çÁö¸¸ ¾ÆÁ÷ ÇØ°áµÇÁö ¾ÊÀº ¹®Á¦Á¡ÀÌ ÀûÁö ¾Ê´Ù.
ÀÌ¿¡ »ç¾÷´ÜÀº Â÷¼¼´ë¿°±â¼¿ºÐ¼®¹ý(NGS)À» ÀÌ¿ëÇÑ Á¶Á÷ÀûÇÕ°Ë»ç¹ý °³¹ßÀ» À§ÇØ À̹ø Çà»ç¸¦ ¸¶·ÃÇß´Ù.
½ÉÆ÷Áö¾öÀº ¡ãClinical importance of HLA typing : ±èÈñÁ¦ ±³¼ö(¼¿ï¼º¸ðº´¿ø), Çã±ÔÇÏ ±³¼ö(¼¼ºê¶õ½ºº´¿ø) ¡ãApplication of NGS : ±èÅÂ±Ô ±³¼ö(°¡Å縯ÀÇ´ë), ±è¿ë±¸ ±³¼ö(¼¿ï¼º¸ðº´¿ø)ÀÇ °¿¬À¸·Î ÁøÇàµÆ´Ù.
ƯÈ÷ Àå±âÀÌ½Ä ¹× Á¶Ç÷¸ð¼¼Æ÷À̽Ŀ¡¼ Á¶Á÷ÀûÇÕ¼ºÇ׿ø(HLA)°Ë»çÀÇ ÀÓ»óÀû Á߿伺 ¹× Á¶Ç÷¸ð¼¼Æ÷ ±âÁõ Èñ¸ÁÀÚÀÇ Á¶Á÷ÀûÇÕ¼ºÇ׿ø¿¡ ´ëÇÑ Â÷¼¼´ë¿°±â¼¿ºÐ¼®¹ý(Next Generation Sequencing, NGS)¿¡ ´ëÇÑ ¹ßÇ¥°¡ ÀÌ·ïÁ³´Ù.
¾çö¿ì ¼±µµÇü ¸é¿ªÁúȯÀ¶ÇÕ¿¬±¸»ç¾÷´ÜÀåÀº "À̹ø ½ÉÆ÷Áö¾öÀ» ÅëÇØ ¼¿ï¼º¸ðº´¿øÀÌ Àå±âÀÌ½Ä ¹× Á¶Ç÷¸ð¼¼Æ÷À̽ÄÀÇ ¼±µµ º´¿øÀ¸·Î¼ °¡Ä¡¸¦ ´õ¿í »ó½Â½ÃŰ°í °íÅë ¹Þ´Â È¯¿ìµé¿¡°Ô µµ¿òÀÌ µÇ´Â °è±â°¡ µÉ °Í"À̶ó°í ¸»Çß´Ù. |